Back

Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Best Posters 5 - Best Posters in antiplatelet agents in acute coronary syndromes Thrombosis and platelets ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Eliano Pio Navarese

Clinical and Interventional Cardiology, Sassari University Hospital, Sassari (Italy)

4 More presentations in this session

Presentation thumbnail
Discussant: Best Posters in antiplatelet agents in acute coronary syndromes
Presentation thumbnail
Comparison of Prescription and Bleeding Rates and Clinical Outcomes of Contemporary P2Y12 Inhibitors in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Assistant Professor J. Choe (Pusan, KR)
Abstract Slides
Presentation thumbnail
Ticagrelor- and prasugrel-mediated platelet inhibition is not affected by mild therapeutic hypothermia generated in vitro in patients with an acute myocardial infarction
Doctor I. Buera Surribas (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Influence of amlodipine on antiplatelet effect of clopidogrel in patients treated with percutaneous coronary intervention: result of the randomized, prospective, two-period, crossover, ACCEL-CCB trial
Professor Y. Jeong (Gwangmyeong, KR)
Abstract Slides

Access the full session

Session thumbnail
Best Posters 5 - Best Posters in antiplatelet agents in acute coronary syndromes

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources